IMR Press / FBL / Volume 13 / Issue 11 / DOI: 10.2741/2997

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Article
Therapeutic implications of the nuclear factor-kappaB/nuclear receptor cross-talk
Show Less
1 Laboratory for Eukaryotic Gene Expression and Signal Transduction ( LEGEST), Department of Molecular Biology, Ghent University, K.L. Ledeganckstraat 35, 9000 Gent, Belgium

*Author to whom correspondence should be addressed.

 

Front. Biosci. (Landmark Ed) 2008, 13(11), 4122–4143; https://doi.org/10.2741/2997
Published: 1 May 2008
Abstract

More and more evidence reveals that the transcription factor NF-kappaB plays a critical role in tumor development and progression and that it may constitute the missing link between inflammation and cancer. It turned out that many of the well known cancer drugs exert their anti-tumoral effect at least in part through modulating the activity of NF-kappaB. The potential of nuclear receptors to modulate the activity of this widespread transcription factor has repeatedly been reported and illustrates their enormous therapeutic potential. However, the efficacy of these liganded receptors is overshadowed by the occurrence of unwanted effects owing to their broad range of actions. Accordingly, researchers pursue the ambition to improve the specificity of nuclear receptor modulators. In this review we have explored the molecular mechanisms by which nuclear receptors interfere with NF-kappaB signalling and quoted the therapeutic implications of their cross-coupling. Strategies that are explored at the moment and that may hold great potential for the future are extensively reviewed.

Share
Back to top